By Lina carolina 
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have identified a crucial protein, CD74, whose expression levels may accurately predict which patients with bowel cancer are most likely to benefit from life-saving immunotherapy treatments. This groundbreaking discovery, published today in the esteemed journal Cancer Cell, holds the potential to significantly expand the pool of eligible patients for these advanced therapies, potentially opening the door for hundreds, if not thousands, of individuals previously deemed ineligible to receive this powerful form of treatment.
The implications of this research are profound for bowel cancer, the fourth most common cancer in the United Kingdom and the second leading cause of cancer-related mortality. The disease is broadly categorized into two distinct subtypes: the "deficient" subtype, characterized by defects in DNA repair mechanisms, and the "proficient" subtype, where these repair systems are intact. While immunotherapy drugs, which harness the patient’s own immune system to combat cancer, have dramatically altered the treatment landscape for the deficient subtype, their efficacy remains limited. These revolutionary treatments only prove effective in approximately half of these patients. Even more significantly, individuals diagnosed with the proficient subtype, representing a vast majority—around 90%—of all bowel cancer cases, are currently excluded from immunotherapy as a treatment option. This new research directly addresses this critical unmet need, aiming to rectify the disparity in access to potentially life-extending therapies.
Unraveling the Immune Microenvironment’s Role in Treatment Response
The scientific endeavor to understand why immunotherapy works for some but not others, and how to broaden its applicability, has been a complex and multi-faceted investigation. The research team, led by Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, delved deep into the intricate interplay between the immune system and the tumor microenvironment. Their initial focus was on the immune cells that surround cancerous growths, as their presence, type, and proximity are known to exert considerable influence on a patient’s response to immunotherapy.
The researchers meticulously examined tumor samples from both deficient and proficient subtypes, comparing those who had responded positively to immunotherapy drugs with those who had not. This detailed analysis revealed a critical requirement for the presence of three specific types of immune cells for a successful response to treatment: cytotoxic T cells and Natural Killer (NK) cells, often referred to as "fighter cells" due to their direct role in eliminating cancer cells, and macrophages. Macrophages play a vital role in the immune system by engulfing cellular debris and pathogens, and importantly, by presenting antigens—molecular flags—on their surfaces to alert other immune cells, such as T cells, to the presence of a threat.
When all three of these crucial immune cell populations—T cells, NK cells, and macrophages—were found to be present and in close proximity to the cancer cells, a significant cascade of molecular signaling was observed. Specifically, the T cells released potent molecules known as interferons. These interferons acted as signaling molecules, triggering a response in both macrophages and the tumor cells themselves. This intricate signaling pathway was markedly more active in tumors of the deficient subtype that had responded favorably to immunotherapy.
However, the study uncovered a surprising revelation: a subset of patients with the proficient subtype also exhibited a comparable level of this crucial immune signaling. This finding strongly suggested that, in these specific proficient cases, the immune system might already be primed or in the "right state" to effectively engage with and benefit from immunotherapy, even though they were not traditionally considered eligible. This observation served as a critical stepping stone in identifying a potential predictive marker that transcends the established subtype classification.
CD74: A Promising Biomarker for Immunotherapy Efficacy
Building upon the insights gained from analyzing the immune microenvironment, the research team sought a more direct and readily measurable indicator of this optimal immune state. Their quest led them to investigate the protein CD74. Employing a cutting-edge technique called spatial transcriptomics, which allows for the detailed analysis of gene expression within specific spatial locations of a tissue sample, they observed a direct correlation between T cell activity and CD74 production.
The spatial transcriptomics data revealed that activated T cells stimulated nearby macrophages and tumor cells to produce CD74. Crucially, tumors that were demonstrably responding to immunotherapy drugs exhibited significantly higher levels of CD74 expression. This finding established CD74 not just as a byproduct of immune activity, but as a potential marker directly associated with a responsive tumor microenvironment.
To rigorously validate whether CD74 could serve as a reliable clinical biomarker for predicting immunotherapy response, the researchers expanded their investigation to include data from several international clinical trials. These trials specifically focused on groups of patients with the proficient subtype who were undergoing immunotherapy treatment. The results from this extensive analysis were compelling: patients who responded to immunotherapy consistently showed significantly higher levels of CD74 in their tumor samples compared to those who did not experience a positive outcome.
This independent confirmation across multiple clinical datasets strongly supports the hypothesis that measuring CD74 levels could serve as a potent predictive tool for immunotherapy response in bowel cancer patients, irrespective of their tumor subtype. The immediate and most significant implication of this finding is the potential to identify individuals with the proficient subtype who, despite their classification, possess the underlying immune readiness to benefit from immunotherapy. This could translate into a substantial increase in the number of patients eligible for this advanced treatment modality, offering them a chance at improved outcomes where previously there was none.
Expert Perspectives and Future Directions
The lead researcher, Professor Francesca Ciccarelli, expressed her enthusiasm and the profound potential of these findings. "Immunotherapy drugs can be hugely successful for people with bowel cancer," she stated, "but currently the majority of patients can’t be prescribed these drugs and, even when patients are eligible, we don’t know upfront who will respond." She elaborated, "Our work suggests that testing for CD74 levels—which signal that the immune system is ‘just right’ to fight the tumour—could widen access to immunotherapy. This could revolutionise treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily."
Kalum Clayton, a former postdoc at the Crick and joint first author of the study alongside Pietro Andrei and Amelia Acha, highlighted the power of advanced technologies in addressing clinical challenges. "Our work shows how state-of-the-art technologies coupled with computational analysis can address important clinical questions," Clayton remarked. "As an early career research scientist, seeing the potential of our work to provide benefit to patients and their families is greatly rewarding."
The research team is actively working to translate these promising laboratory findings into a tangible clinical tool. In collaboration with Cancer Research Horizons, they are developing a diagnostic test that can be readily implemented in clinical settings. Beyond the development of the test, further research is planned to elucidate the precise biological mechanisms by which macrophages and tumor cells overexpress CD74. Additionally, the team intends to investigate whether this predictive marker for immunotherapy response is also present in other types of cancer, potentially broadening its clinical utility even further.
Anna Kinsella, Science Engagement Manager at Cancer Research UK, emphasized the significance of such discovery research. "Immunotherapy treatments, such as immune checkpoint inhibitors, use the power of the immune system to fight cancer," Kinsella explained. "Whilst these treatments benefit some people with bowel cancer, they aren’t effective for everyone. Although further research is needed, studies like this—diving deep into the biology of tumours—help researchers find ways to predict when immunotherapy is likely to work. In the future, this could help clinicians tailor treatment and allow more people with bowel cancer to benefit from immunotherapy." She concluded by underscoring Cancer Research UK’s commitment to fundamental research: "Understanding the biology of cancer is vital to unlocking better ways to prevent, detect and treat it, so that people can live longer, better lives free from the fear of cancer. That’s why at Cancer Research UK, discovery research is at the heart of everything we do."
The collaborative nature of this research is also noteworthy, with contributions from institutions including UCL, the University of Pisa, King’s College London, the Sarah Cannon Research Institute, and the Veneto Institute of Oncology, underscoring a global effort to advance cancer care.
Broader Implications and the Path Forward
The discovery of CD74 as a predictive biomarker for immunotherapy response in bowel cancer carries significant implications beyond the immediate patient group. For decades, the classification of cancers has primarily relied on anatomical location and histological characteristics. However, the burgeoning field of precision medicine increasingly emphasizes the molecular and immunological profiles of tumors to guide treatment decisions. This research exemplifies this paradigm shift, demonstrating how a deeper understanding of the tumor microenvironment can unlock new therapeutic avenues.
The current landscape of immunotherapy in bowel cancer, while revolutionary for the deficient subtype, has been hampered by its limited applicability. For the proficient subtype, standard treatment options often involve chemotherapy and surgery, which, while effective, can carry significant side effects and may not always achieve long-term remission. The prospect of offering immunotherapy to a broader segment of these patients, based on a reliable predictive marker, represents a substantial leap forward in personalized cancer care. It could lead to improved treatment efficacy, potentially higher remission rates, and a better quality of life for patients by avoiding less effective or more toxic treatments.
Furthermore, the ability to identify patients within the deficient subtype who are unlikely to respond to immunotherapy is equally important. This would allow clinicians to proactively steer these patients towards alternative treatment strategies that may be more beneficial, while simultaneously sparing them the potential side effects and financial burden associated with ineffective therapies. This nuanced approach to treatment selection is a hallmark of advanced cancer care.
The timeline of this research, from initial hypothesis to publication, represents a significant scientific undertaking. While the exact start date of the project is not detailed, the publication in Cancer Cell signifies the culmination of years of rigorous experimentation, data analysis, and peer review. The current stage of developing a clinical test suggests that this research is transitioning from the discovery phase to the translational phase, a critical step in bringing scientific breakthroughs from the laboratory to the patient bedside.
The success of this study also highlights the increasing importance of interdisciplinary collaboration in biomedical research. The integration of expertise in cancer biology, immunology, genomics, and computational analysis, across multiple leading research institutions, was instrumental in achieving these complex findings. The use of advanced technologies like spatial transcriptomics is a testament to the evolving toolkit available to researchers, enabling them to probe biological systems with unprecedented detail.
Looking ahead, the validation of CD74 as a routine clinical biomarker will require further large-scale prospective studies to confirm its predictive accuracy across diverse patient populations and treatment settings. Regulatory approval processes will also need to be navigated before the test can be widely adopted. However, the strong evidence presented in this study provides a robust foundation for these future endeavors. The potential for CD74 to become a standard component of bowel cancer diagnostic workups, guiding immunotherapy decisions, is a tangible and exciting prospect that promises to reshape the future of bowel cancer treatment.
